AAM Speaks Out Against Build Back Better Bill
US Pricing Policy Could Unfairly Penalize Generics And Biosimilars Manufacturers
The US Association for Accessible Medicines has panned the Biden administration’s Build Back Better Act, which it says threatens patient access to affordable drugs in its current form.
You may also be interested in...
Concerns that Medicare drug price negotiation provisions in the Build Back Better legislation would upend the US generic and biosimilar industries might resonate with legislators more than complaints from branded drug companies.
The legislation would also establish new manufacturer discounts in Medicare Part D as part of a redesign of the benefit that includes a cap on beneficiary out-of-pocket spending. Negotiations are still fluid on the overall legislative package, however, and things could change.
Savings achieved in the US through the use of generics and biosimilars hit a new high in 2020, reaching $338bn, according to new figures released by the AAM.